Trial
NCT01118351
Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Case Comprehensive Cancer Center
Collaborators
Pfizer
Condition
Recurrent Bladder Cancer
Intervention
sunitinib malate
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-05-01